Selenium Supplementation by Addition of Sodium Selenate with Silage
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Sodium Selenate Hazard Summary Identification
Common Name: SODIUM SELENATE CAS Number: 13410-01-0 RTK Substance number: 1726 DOT Number: UN 2630 Date: November 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Sodium Selenate can affect you when breathed in and The following exposure limits are for Selenium compounds may be absorbed through the skin. (measured as Selenium): * Contact can irritate the skin and eyes. * Breathing Sodium Selenate can irritate the nose, throat OSHA: The legal airborne permissible exposure limit 3 and lungs causing coughing, wheezing and/or shortness of (PEL) is 0.2 mg/m averaged over an 8-hour breath. workshift. * High exposure can cause headache, nausea, vomiting, NIOSH: The recommended airborne exposure limit is coated tongue, metallic taste and garlic odor on the breath. 3 * Repeated exposure can cause pallor, nervousness and 0.2 mg/m averaged over a 10-hour workshift. mood changes. ACGIH: The recommended airborne exposure limit is * Sodium Selenate may damage the liver and kidneys and 3 affect the heart. 0.2 mg/m averaged over an 8-hour workshift. * The above exposure limits are for air levels only. When IDENTIFICATION skin contact also occurs, you may be overexposed, even Sodium Selenate is a white, sand-like solid. It is used as a though air levels are less than the limits listed above. medication and an insecticide. WAYS OF REDUCING EXPOSURE REASON FOR CITATION * Where possible, enclose operations and use local exhaust * Sodium Selenate is on the Hazardous Substance List ventilation at the site of chemical release. If local exhaust because it is regulated by OSHA and cited by ACGIH, ventilation or enclosure is not used, respirators should be DOT, NIOSH, DEP and EPA. -
Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1
[CANCER RESEARCH 49, 3168-3172, June 15, 1989] Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1 David L. McCormick,2 Ann M. Spicer, and Jacqueline L. Hollister Life Sciences Department, IIT Research Institute, Chicago, Illinois 60616 ABSTRACT studies with this class of compounds used inhibitors of the cyclooxygenase pathway of arachidonic acid catabolism; exper Neoplastic development in the rat mammary gland can be suppressed iments performed in our laboratory and by Ip and coworkers by inhibition of the activity of several enzymes involved in eicosanoid biosynthesis. In order to investigate the potential utility of prostacyclin demonstrated that the postcarcinogen phase of rat mammary and thromboxane synthetases as targets for mammary cancer chemopre- carcinogenesis can be suppressed by dietary administration of vention, experiments were conducted to determine the influence of tran- indomethacin (7, 8) or flurbiprofen (9). However, although the ylcypromine (TCP), an inhibitor of prostacyclin synthetase, and ¡mida/ole anticarcinogenic activity of indomethacin is similar to that of (IMI), an inhibitor of thromboxane synthetase, on mammary carcinogen- more widely studied inhibitors of mammary carcinogenesis such esis induced in rats by 7V-methyl-/V-nitrosourea. Fifty-day-old female as retinyl acetate (10) and selenium (11), the dose levels of Sprague-Dawley |Hsd:SD(BR)l rats received a single s.c. dose of 0 or 40 indomethacin required for chemopreventive efficacy in rats are mg of .V-mcth>l-.Y-nitrosoiirea per kg of body weight. Beginning 7 days close to the threshold of lethal toxicity (12). For this reason, after carcinogen administration, groups of rats were fed isoenergetic, studies are ongoing to identify additional modifiers of arachi casein-based diets containing 3 or 20% corn oil (w/w), supplemented with donic acid metabolism whose administration provides an effec (per kg of diet) 10 mg of TCP, 1000 mg of IMI, or sucrose carrier only. -
Curative Effect of Selenium Against Indomethacin-Induced Gastric Ulcers in Rats
J. Microbiol. Biotechnol. (2011), 21(4), 400–404 doi: 10.4014/jmb.1012.12019 First published online 19 January 2011 Curative Effect of Selenium Against Indomethacin-Induced Gastric Ulcers in Rats Kim, Jeong-Hwan1, Byung-Woo Kim1,3,4, Hyun-Ju Kwon1,3,4, and Soo-Wan Nam1,2,4* 1Department of Biomaterial Control, 2Department of Biotechnology and Bioengineering, 3Department of Life Science and Biotechnology, and 4Blue-Bio Industry RIC, Dong-Eui University, Busan 614-714, Korea Received: December 16, 2010 / Revised: December 30, 2010 / Accepted: December 31, 2010 Indomethacin is a nonsteroid anti-inflammatory agent erosions, ulcerative lesions, and petechial bleeding in the that is known to induce severe gastric mucosal lesions. In mucosa of stomach as serious side effects [10, 18]. According this study, we investigated the effect of selenium on gastric to previous reports, the oral administration of indomethacin in mucosal lesions in rats. To confirm the curative effect of rats causes ulcerative lesions in the gastric mucosa [7, 13]. selenium against indomethacin-induced gastric ulcers, Furthermore, the development of the gastric mucosal lesions gastric ulcers were induced by oral administration of induced by indomethacin is mainly mediated through 25 mg/kg indomethacin, and then different doses (10, 50, generation of oxygen free radicals and lipid peroxidation and 100 µg/kg of body weight) of selenium or vehicle were [6, 22, 25, 26, 28, 29]. treated by oral gavage for 3 days. Oral administration of Selenium is an essential nutrient of fundamental importance indomethacin clearly increased the gastric ulcer area in to human biology. It has important metabolic functions in the stomach, whereas selenium applied for 3 days significantly animals, including protection of membrane lipids and decreased the gastric ulcer area in a dose-dependent macromolecules from oxidative damage produced by peroxides manner. -
Potential Adverse Effects of Resveratrol: a Literature Review
International Journal of Molecular Sciences Review Potential Adverse Effects of Resveratrol: A Literature Review Abdullah Shaito 1 , Anna Maria Posadino 2, Nadin Younes 3, Hiba Hasan 4 , Sarah Halabi 5, Dalal Alhababi 3, Anjud Al-Mohannadi 3, Wael M Abdel-Rahman 6 , Ali H. Eid 7,*, Gheyath K. Nasrallah 3,* and Gianfranco Pintus 6,2,* 1 Department of Biological and Chemical Sciences, Lebanese International University, 1105 Beirut, Lebanon; [email protected] 2 Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; [email protected] 3 Department of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar; [email protected] (N.Y.); [email protected] (D.A.); [email protected] (A.A.-M.) 4 Institute of Anatomy and Cell Biology, Justus-Liebig-University Giessen, 35392 Giessen, Germany; [email protected] 5 Biology Department, Faculty of Arts and Sciences, American University of Beirut, 1105 Beirut, Lebanon; [email protected] 6 Department of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O Box: 27272, United Arab Emirates; [email protected] 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236 Beirut, Lebanon * Correspondence: [email protected] (A.H.E.); [email protected] (G.K.N.); [email protected] (G.P.) Received: 13 December 2019; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Due to its health benefits, resveratrol (RE) is one of the most researched natural polyphenols. -
Common Name: SELENIUM SULFIDE HAZARD SUMMARY
Common Name: SELENIUM SULFIDE CAS Number: 7446-34-6 RTK Substance number: 1653 DOT Number: UN 2657 Date: October 1995 Revision: October 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY * Selenium Sulfide can affect you when breathed in and by * If you think you are experiencing any work-related health passing through your skin. problems, see a doctor trained to recognize occupational * Selenium Sulfide should be handled as a CARCINOGEN- diseases. Take this Fact Sheet with you. -WITH EXTREME CAUTION. * Contact can irritate the eyes with possible eye damage. WORKPLACE EXPOSURE LIMITS * Breathing Selenium Sulfide can irritate the nose and The following exposure limits are for Selenium compounds throat. (measured as Selenium): * High exposure may cause headache, nausea, vomiting, garlic odor of the breath, metallic taste and coated tongue. OSHA: The legal airborne permissible exposure limit * Repeated exposure can cause pallor, nervousness and (PEL) is 0.2 mg/m3 averaged over an 8-hour mood changes. workshift. * Selenium Sulfide may damage the liver and kidneys. NIOSH: The recommended airborne exposure limit is IDENTIFICATION 0.2 mg/m3 averaged over a 10-hour workshift. Selenium Sulfide is a bright orange powder. It is used in medicated shampoos. ACGIH: The recommended airborne exposure limit is 3 0.2 mg/m averaged over an 8-hour workshift. REASON FOR CITATION * Selenium Sulfide is on the Hazardous Substance List * Selenium Sulfide may be a CARCINOGEN in humans. because it is regulated by OSHA and cited by ACGIH, There may be no safe level of exposure to a carcinogen, so DOT, NIOSH, NTP, DEP, HHAG and EPA. all contact should be reduced to the lowest possible level. -
Role of Selenium in HIV Infection
Role of selenium in HIV infection The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Stone, Cosby A, Kosuke Kawai, Roland Kupka, and Wafaie W Fawzi. 2010. “Role of Selenium in HIV Infection.” Nutrition Reviews 68 (11) (October 20): 671–681. doi:10.1111/j.1753-4887.2010.00337.x. Published Version doi:10.1111/j.1753-4887.2010.00337.x Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26951080 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Nutr Rev. Author manuscript; available in PMC 2011 November 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nutr Rev. 2010 November ; 68(11): 671±681. doi:10.1111/j.1753-4887.2010.00337.x. The Role of Selenium in HIV Infection Cosby A Stone, Kosuke Kawai, Roland Kupka, Wafaie W Fawzi Harvard School of Public Health Cosby A Stone, School of Public Health and School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA Kosuke Kawai, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA Roland Kupka, and Department of Nutrition, Harvard School of Public Health, Boston, MA, USA and United Nations Children’s Fund, Regional Office for West and Central Africa, Dakar, Senegal Wafaie W. -
Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-Administration of Selenium/ Tribulus Terrestris Extract in Rats
Int. J. Morphol., 38(5):1444-1454, 2020. Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-administration of Selenium/ Tribulus terrestris Extract in Rats Hepatotoxicidad Inducida por la Dosis Terapéutica de Acetaminofén y el Efecto de Mejora de la Administración Conjunta de Extracto de Selenio Tribulus terrestris en Ratas Amin A. Al-Doaiss1,2 AL-DOAISS, A. A. Hepatotoxicity-induced by the therapeutic dose of acetaminophen and the ameliorative effect of oral co-administration of selenium / Tribulus terrestris extract in rats. Int. J. Morphol., 38(5):1444-1454, 2020. SUMMARY: Over dose or long-term clinical use of therapeutic doses of acetaminophen (APAP) causes hepatotoxicity. Various strategies attempted to ameliorate APAP-hepatotoxicity have been found to be unsuitable for clinical practice. This study was aimed to illustrate the histopathological changes induced by therapeutic dose of APAP and investigate the hepatoprotective role of oral co- administration of selenium/ Tribulus terrestris (TT) extract concurrently against hepatotoxicity induced by APAP in rats. Fifty-four healthy male albino Wistar rats were randomized into nine groups (G1–G9) of six rats each, and administered with APAP and TT orally for 30 days as follows: Control (2ml normal saline), APAP (470 mg/kg), APAP (470 mg/kg) + selenium (2 mg/kg), APAP (470 mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + selenium (2mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + silymarin (200 mg/kg), selenium (2 mg/ kg), TT (98 mg/kg) and silymarin (200 mg/kg) groups. The results demonstrated that exposure of rats to therapeutic dose of APAP for 30 days caused significant histopathological changes parallel to elevated blood chemistry parameters. -
(12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji Et Al
US00721 1656B2 (12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji et al. (45) Date of Patent: May 1, 2007 (54) DESATURASE GENES, ENZYMES ENCODED Doerks et al., TIG 14(6): 248-250, Jun. 1998.* THEREBY, AND USES THEREOF Smith et al. Nature Biotechnology 15: 1222-1223, Nov. 15, 1997.* Brenner, S.E., TIG 15(4): 132-133, Apr. 1999.* (75) Inventors: Pradip Mukerji, Gahanna, OH (US); Bork et al., TIG 12(10): 425-427, Oct. 1996.* Suzette L. Pereira, Westerville, OH Leslie, C. G. et al., “Dietary (n-9) Eicosatrienoic Acid from a (US); Yung-Sheng Huang, Upper Cultured Fungus Inhibits Leukotriene B4 Synthesis in Rats and the Arlington, OH (US) Effect Is Modified by Dietary Linoleic Acid' ', Amer Journ of Clin Nutrit, 126(6): 1534-1540 (1996). Jareonkitmongkol, S., et al., “Production of an Eicosapentaenoic (73) Assignee: Abbott Laboratories, Abbott Park, IL Acid-Containing Oil by a A12 Desaturase-Defective Mutant of (US) Mortierella alpina 1S-4”, Journ of the Amer Oil Chemists Soc. 70(2): 119-123 (1993). (*) Notice: Subject to any disclaimer, the term of this Pereira, S.L., et al., “A novel (p-fatty acid desaturase involved in the patent is extended or adjusted under 35 biosynthesis of eicosapentaenoic acid”. The Biohem Journ, U.S.C. 154(b) by 444 days. 378(2):665-671 (2004). Ziboh, V.A., et al., Metabolism of polyunsaturated fatty acids by (21) Appl. No.: 10/060,793 skin epidermal enzymes: generation of anti-inflammatory and antiproliferative metabolites 1-3, Amer Journ of Clin Nutri, (22) Filed: Jan. -
Felix Ekness
ABSTRACT A Synthetic Biology Approach to Engineering Bacterial Two- Component Systems for Sensor Development and Discovery of Anti-Virulence Agents by Felix Ekness Bacterial two-component systems (TCSs) are the largest family of signal transduction pathways that enable bacteria to sense a diversity of stimuli including small peptides, environmental pollutants, and light. Canonical TCSs are composed of a transmembrane sensor histidine kinase (SK) that converts stimulus detection into phosphorylation of a cognate response regulator (RR). Upon phosphorylation, the cytoplasmic RR binds target output promoters, hereby modulating gene expression. TCSs are valuable sensors for synthetic biology due to their diverse sensing capabilities and straightforward transduction of detected stimulus into transcriptional regulation. TCSs are also emerging targets for novel therapeutic development due to their extensive role in regulating bacterial virulence and antibiotic resistance. Although TCSs are exciting sensors for synthetic biology and targets for therapeutic applications, most TCSs remain difficult to harness for applications and study due to output promoters that are unknown, subject to cross- regulation, or silent in heterologous hosts. In the first portion of my work, I develop a method to overcome the hurdles in characterizing and utilizing TCSs as biosensors. Through the framework of synthetic biology, I demonstrate that the two largest families of RR DNA binding domains (DBDs) can be interchanged with remarkable flexibility, enabling the corresponding TCSs to be rewired to synthetic output promoters. In collaboration with Kristina Daeffler, we exploit this plasticity to eliminate cross-regulation and in collaboration with Brian Landry, we un-silence a gram-negative TCS in a gram-positive host and engineer a sensor with over 1,300-fold activation. -
HYPERFORIN PROMOTES MITOCHONDRIAL FUNCTION and DEVELOPMENT of OLIGODENDROCYTES a Thesis Submitted to the College of Graduate
HYPERFORIN PROMOTES MITOCHONDRIAL FUNCTION AND DEVELOPMENT OF OLIGODENDROCYTES A Thesis Submitted to the College of Graduate Studies and Research in Partial Fulfillment of the Requirements for a Master’s Degree in the Department of Psychiatry University of Saskatchewan Saskatoon By Yanlin Wang © Copyright Yanlin Wang, December 2009. All rights reserved. PERMISSION TO USE In presenting this thesis in partial fulfillment of the requirements for a Master’s degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to: Head, the Department of Psychiatry University of Saskatchewan Saskatoon, Saskatchewan Canada, S7N 5E4 i ABSTRACT Major depressive disorder is a common severe psychiatric disorder with unknown etiology. Recent studies show that the loss and malfunction of oligodendrocytes are closely related to the neuropathological changes in depression, which can be reversed by antidepressant treatment. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Antidepressant Effect of ß-Hydroxy-ß-Methylbutyrate
(19) TZZ Z_T (11) EP 2 745 708 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 25.06.2014 Bulletin 2014/26 A23L 1/305 (2006.01) A23L 1/29 (2006.01) A61K 31/19 (2006.01) A61P 25/24 (2006.01) (21) Application number: 12382531.7 (22) Date of filing: 24.12.2012 (84) Designated Contracting States: • Barranco-Pérez, Alejandro AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 18110 LAS GABIAS (Granada) (ES) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Rueda Cabrera, Ricardo PL PT RO RS SE SI SK SM TR 18008 GRANADA (ES) Designated Extension States: • Bespalov, Anton BA ME 69118 HEIDELBERG (DE) • Behl, Berthold (71) Applicant: Abbott Laboratories, Inc. 67098 BAD DUERKHEIM (DE) Abbott Park, IL 60064 (US) • Van Gaalen, Marcel M. 67433 NEUSTADT AN DER WEINSTRASSE (DE) (72) Inventors: • Ramírez, María (74) Representative: Ungria López, Javier 18003 GRANADA (ES) Avda. Ramón y Cajal, 78 28043 Madrid (ES) (54) Antidepressant effect of ß-hydroxy-ß-methylbutyrate (57) A method of treating or preventing depression method of treating or preventing a condition which can using β-hydroxy-β-methylbutyrate (HMB) is described. be improved or prevented by the activation of mTOR sig- The method includes administering an effective amount naling by administering an effective amount of HMB or a of HMB or a pharmaceutically acceptable salt thereof to pharmaceutically acceptable salt thereof to a subject in a subject in need thereof. The HMB can be administered need thereof. as part of a nutritional composition.